# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN
- Date: 2026-08-31
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Holiday is a 33-year-old singer with a severe opioid use disorder on buprenorphine and a moderate alcohol use disorder on acamprosate, who comes for her yearly preventive visit six weeks after her three-month review. Since that visit, when the recovery plan was adjusted after a brief return to use on tour, she has taken buprenorphine every day without a gap and has used no heroin or other opioids. The pharmacy now fills her prescription before each tour, and she carries a travel letter. She drinks one or two drinks on some performance nights and none on most other days. She still carries naloxone and fentanyl test strips. She meets her counselor weekly and her peer recovery coach by phone. Her mood is better, and her PHQ-9 today is 6. She has no new concerns. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 33 |
| Opioid use | None since the return to use before the three-month visit; buprenorphine daily without gaps |
| Alcohol | One or two drinks on some performance nights; AUDIT-C 3 |
| Mood | PHQ-9 6; item 9 scored 0 |
| Medicines | Buprenorphine with naloxone 16 mg daily; acamprosate 666 mg three times daily; thiamine; naloxone spray on hand |

## Health risk assessment

Completed by the patient on paper in a private room and reviewed with her by Dr. Mayfield; kept in the confidential part of the record with her substance use treatment records. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than in the spring |
| Psychosocial | Supported by long-time musicians, a close friend, her counselor, and a peer recovery coach; grief for her mother still returns at times |
| Substance use | No opioid use for six weeks on buprenorphine; AUDIT-C 3 |
| Tobacco | About five cigarettes a day |
| Physical activity | Walks most days; performing is physically demanding |
| Nutrition | Irregular meals on performance days; eating more regularly at home |
| Sleep | Six to seven hours, better than at intake |
| Sexual and reproductive health | Sexually active; uses condoms; not planning a pregnancy now |
| Safety at home | Feels safe at home; no one hurts or threatens her |
| Road safety | Wears a seat belt |
| Activities of daily living | Independent |
| Oral health | No dental visit in several years |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No hoarseness or voice change; no dental pain |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal pain, vomiting, black stools, or yellowing of the skin; constipation settled with fiber |
| Genitourinary | Negative | No abnormal bleeding or discharge |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No skin infections or abscesses |
| Neurological | Negative | No numbness, tremor, or unsteadiness |
| Psychiatric | Negative | Mood better; PHQ-9 score 6; no thoughts of suicide or self-harm; cravings occasional and manageable |

11 systems reviewed. **S**

## Current medications

- Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 68.8 kg; BMI 25.3 kg/m². All vital signs are synthetic.

PHQ-9: 6; AUDIT-C: 3. All results are synthetic.

## Change since baseline

- PHQ-9: 9 at baseline, 6 at this visit **S**
- AUDIT-C: 8 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 68.8 kg, BMI 25.3; blood pressure 118/76 |
| Eyes | No scleral icterus |
| Mouth | Several teeth with visible decay; no abscess |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; liver edge not palpable; no spleen enlargement |
| Skin | No spider angiomas, palmar erythema, track marks, or abscesses |
| Neurological | No tremor; gait steady |
| Psychiatric | Calm and engaged; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Cervical screening and sexual-health tests are due, and dental care is overdue. **S**
   - Next preventive visit in one year.
2. **Opioid use disorder on buprenorphine** (F11.20). Six weeks without opioid use since the plan was adjusted; no gaps in buprenorphine. Safety reviewed: no thoughts of suicide or self-harm; she has naloxone, test strips, and the 988 Suicide & Crisis Lifeline saved in her phone. **S**
   - Continue buprenorphine with naloxone 16 mg daily.
   - Six-month recovery review in seven weeks.
3. **Alcohol use disorder on acamprosate** (F10.20). Drinking much reduced; AUDIT-C 3. **S**
   - Continue acamprosate and thiamine; PEth and liver tests at six months.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/76 mmHg |
| Cervical cancer screening | Ordered | No result on record; cytology with HPV testing collected today; every five years if normal |
| Chlamydia and gonorrhea screening | Ordered | Offered because of new partners in the past year; urine test today with her agreement |
| Syphilis screening | Ordered | Offered with the other sexual-health tests; drawn today |
| HIV, hepatitis C, and hepatitis B screening | Up to date | All nonreactive at intake; repeat yearly while any drug use continues |
| Pregnancy intention and contraception | Completed today | Not planning a pregnancy; uses condoms; other methods discussed and she will think about them. Buprenorphine is safe to continue in pregnancy, and she was told so |
| Intimate partner violence screening | Completed today | Negative; she feels safe at home |
| Depression screening | Completed today | PHQ-9 score 6, down from 11 six weeks ago; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 3, from 8 at intake; in treatment |
| Tobacco cessation | Declined | About five cigarettes a day; nicotine replacement and counseling offered; she is not ready and will say when she is |
| Diabetes and cholesterol screening | Not indicated | Diabetes screening begins at 35 for adults who are overweight; statin assessment begins at 40 |
| Breast and colorectal cancer screening | Not indicated | Begin at 40 and 45 |
| Hepatitis A vaccine | Due | Dose 2 at the six-month visit |
| Hepatitis B vaccine | Up to date | Two-dose series complete |
| Pneumococcal vaccine | Up to date | PCV20 at intake, recommended for adults with alcohol use disorder |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap at intake |
| Influenza and COVID-19 vaccines, this season | Due | Influenza vaccine at the six-month visit; COVID-19 vaccine discussed and she will decide then |
| HPV vaccine | Declined | Shared decision-making for adults 27 to 45; she chose not to have it |
| Dental examination | Referred | Visible decay and no dental visit in several years; dry mouth from buprenorphine discussed; dental appointment arranged |

## Advance care planning

Voluntary advance care planning discussion of about 16 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the confidential part of the chart and is not named here. She said that what matters most to her is her music, being treated with respect, and deciding for herself who learns about her health. She chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. **S**

## Guideline basis

- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force

## Follow-up

- Six-month recovery review in seven weeks, with PEth, liver tests, blood count, the second hepatitis A dose, and the influenza vaccine. Sexual-health and cervical screening results by phone, as she asked. Dental appointment arranged. Next preventive visit in one year. **S**
- Next scheduled visit 2026-10-19: six-month recovery, alcohol, liver, and mood review. **S**
